USA – BD has announced the formation of the Sustainable Medical Technology Institute to focus on the company’s environmental impact.

BD’s Sustainable Medical Technology Institute, based in Franklin Lakes, New Jersey, will bring together the company’s researchers and engineers, as well as quality, regulatory, policy, and operational expertise, to focus on reducing the environmental impact of its product portfolio.

The emphasis will be on three areas, according to a news release: adopting sustainable product design strategies, developing and deploying sustainable sterilization technologies, and addressing materials of concern (MOC).

According to BD, the institute will serve as an example of how to advance the world of health by prioritizing high-quality, safe products for patients while furthering the company’s environmental, social and governance (ESG) strategy.

As part of our ESG strategy, we made commitments in specific areas where we see the most opportunity for BD to create meaningful, measurable change over the next decade,” said Maureen Mazurek, vice president, sustainability and environmental health and safety (EHS) at BD.

In order to achieve these commitments, we established a set of goals to track and measure our success, and this includes how to reduce the environmental impact of our product portfolio and address our customers’ sustainability needs. These priorities led us to form the Sustainable Medical Technology Institute.

The Institute will operate in North America, Europe, and Asia, and will collaborate with cross-functional teams within the company’s functional business units, including roles in R&D, regulatory, quality, policy, and operations.

The goal is to ensure accountability and a streamlined approach to sustainability efforts, as well as addressing sustainability needs within the industry and global regulatory bodies.

The company’s initial efforts include reestablishing a set of minimum environmental and human health criteria for new products and product changes that are aligned with its 2030+ ESG commitments and goals, as well as identifying new ways to reduce, reuse, recycle, or replace materials.

These efforts will help to shape the company’s product life cycle roadmap and enable the implementation of a sustainable-by-design product development process.

At the beginning of April BD company announced the completion of its spinoff of Embecta Corp. (embecta) which now owns BD’s former Diabetes Care business and is one of the world’s largest pure-play diabetes management companies.

The embecta spinoff demonstrates BD’s ongoing commitment to the company’s BD 2025 strategy, which includes three strategic pillars: Grow, Simplify, and Empower according to the company’s press release at the time.

The spinoff’s strategic rationale was to create two independent companies with appealing long-term value for BD shareholders and enhanced strategic, operational, and financial characteristics.

Each company will concentrate on its core business and product portfolios, with BD retaining category leadership positions in its BD Medical, BD Life Sciences, and BD Interventional segments.

Embecta will concentrate on expanding on its strong foundation as the leading manufacturer of diabetes injection devices, investing in both organic and inorganic growth opportunities, and improving the lives of people living with diabetes.

Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE